Tracleer\u00ae is the commercial brand name of Bosentan Tablets, an orally active dual endothelin receptor antagonist developed by Actelion. It blocks endothelin ET\u2090 and ET\u1d66 receptors on pulmonary vascular smooth muscle to relax pulmonary arteries, reduce pulmonary vascular resistance and slow vascular remodeling.<\/p>\n\n\n\n
Main Indications<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy Tracleer (Bosentan Tablets)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" Tracleer\u00ae is the commercial brand name of Bosentan Tablets, an orally active dual endothelin receptor antagonist developed by Actelion. It blocks endothelin ET\u2090 and ET\u1d66 receptors on pulmonary vascular smooth muscle to relax pulmonary arteries, reduce pulmonary vascular resistance and slow vascular remodeling. Main IndicationsTreatment of pulmonary arterial hypertension (WHO functional class II\u2013III) in adults […]<\/p>\n","protected":false},"author":4,"featured_media":3492,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-3491","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Treatment of pulmonary arterial hypertension (WHO functional class II\u2013III) in adults to improve exercise tolerance and delay disease progression.<\/p>\n\n\n\n
Common mild adverse reactions: Headache, flushing, peripheral edema, nasal congestion and dyspepsia.
Laboratory abnormalities: Dose-related liver enzyme elevation and anemia.
Severe but manageable risks: Severe hepatic injury, fetal toxicity and severe hypersensitivity.<\/p>\n\n\n\n
Tracleer\u00ae (Bosentan Tablets,125mg, domestic Chinese brand name: Quankeli) was officially approved for marketing in China in 2006. It is currently a prescription drug included in China\u2019s Category B medical insurance.<\/p>\n\n\n\n